Johnson & Johnson to Acquire Intra-Cellular Therapies in a Groundbreaking $14.6 Billion Deal

Johnson & Johnson has agreed to acquire Intra-Cellular Therapies Inc. for $14.6 billion, aiming to enhance its neuroscience portfolio and advance treatment for neuropsychiatric and...